Microenvironment-Driven Modulation of Diiron(I) Bis-Cyclopentadienyl Complex Activity in Advanced Cancer Models

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Oncology

Background:

• Platinum-based chemotherapy faces limitations due to severe side effects and drug resistance.
• Iron complexes offer a biocompatible and abundant alternative for novel anticancer drug development.
• Low-valent iron(I) complexes are underexplored in cancer therapy despite their potential.

Purpose of the Study:

• To investigate the anticancer potential of four diiron(I) bis-cyclopentadienyl complexes.
• To evaluate the influence of the tumor microenvironment on drug response.
• To explore the mechanisms of action, including reactive oxygen species (ROS) modulation and cell death pathways.

Main Methods:

• Cytotoxicity assays across various cancer cell lines (breast, glioblastoma, osteosarcoma).
• Mechanistic studies on ROS generation and programmed cell death.
• Comparative drug evaluation using 2D cell cultures, cancer stem cell (CSC) spheroids, and 3D scaffold-based models.

Main Results:

• The diiron(I) complexes demonstrated cytotoxic activity against tested cancer cell lines.
• Tumor microenvironment complexity significantly impacted drug efficacy.
• Advanced models (spheroids, 3D scaffolds) revealed drug responses not apparent in 2D cultures.

Conclusions:

• Low-valent iron complexes represent a promising class of next-generation metal-based anticancer agents.
• Incorporating microenvironmental factors is crucial for accurate assessment of anticancer drug efficacy.
• Further research into iron-based compounds could lead to improved cancer therapies with reduced side effects.